Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate

Tuesday, June 26, 2012

Dynavax (DVAX): FDA Accepts Hepatitis B Vaccine Biologics License Application

(By Balaseshan) Dynavax Technologies Corp. (NASDAQ:DVAX : 4.4, 0.24) said the Food and Drug Administration (FDA) has accepted for review the U.S. Biologics License Application (BLA) of its investigational adult hepatitis B vaccine.

The company anticipates submitting a European Marketing Authorization Application (MAA) for HEPLISAV in the third quarter of 2012.

Read more...

No comments:

Post a Comment